> For the complete documentation index, see [llms.txt](https://bdcatalyst.gitbook.io/biodata-catalyst-documentation/llms.txt). Markdown versions of documentation pages are available by appending `.md` to page URLs; this page is available as [Markdown](https://bdcatalyst.gitbook.io/biodata-catalyst-documentation/written-documentation/explore-available-data/pic-sure-for-biodata-catalyst-user-guide/appendix/appendix-2-table-of-topmed-dcc-harmonized-variables-in-pic-sure.md).

# Appendix 2: Table of TOPMed DCC Harmonized Variables in PIC-SURE

<table><thead><tr><th width="171">Variable Name</th><th width="239">Variable Description</th><th width="102">TYPE</th><th width="120">UNITS</th><th>VALUES</th></tr></thead><tbody><tr><td>angina_incident_1</td><td>An indicator of whether a subject had an angina event (that was verified by adjudication or by medical professionals) during the follow-up period.</td><td>encoded</td><td></td><td>0=Angina event did not occur during follow-up || 1=Angina event occurred during follow-up</td></tr><tr><td>angina_prior_1</td><td>An indicator of whether a subject had an angina event prior to the baseline visit.</td><td>encoded</td><td></td><td>0=Did not have a history of angina before baseline || 1=Had a history of angina before baseline</td></tr><tr><td>annotated_sex_1</td><td>Subject sex, as recorded by the study.</td><td>encoded</td><td></td><td>female=Female || male=Male</td></tr><tr><td>antihypertensive_meds_1</td><td>Indicator for use of antihypertensive medication at the time of blood pressure measurement.</td><td>encoded</td><td></td><td>0=Not taking antihypertensive medication || 1=Taking antihypertensive medication</td></tr><tr><td>basophil_ncnc_bld_1</td><td>Count by volume, or number concentration (ncnc), of basophils in the blood (bld).</td><td>decimal</td><td>thousands / microliter</td><td></td></tr><tr><td>bmi_baseline_1</td><td>Body mass index calculated at baseline.</td><td>decimal</td><td>kg/m^2</td><td></td></tr><tr><td>bp_diastolic_1</td><td>Resting diastolic blood pressure from the upper arm in a clinical setting.</td><td>decimal</td><td>mmHg</td><td></td></tr><tr><td>bp_systolic_1</td><td>Resting systolic blood pressure from the upper arm in a clinical setting.</td><td>decimal</td><td>mmHg</td><td></td></tr><tr><td>cabg_incident_1</td><td>An indicator of whether a subject had a coronary artery bypass graft (CABG) procedure (that was verified by adjudication or by medical professionals) during the follow-up period.</td><td>encoded</td><td></td><td>0=CABG procedure did not occur during follow-up || 1=CABG procedure occurred during follow-up</td></tr><tr><td>cabg_prior_1</td><td>An indicator of whether a subject had a coronary artery bypass graft (CABG) procedure prior to the start of the baseline visit.</td><td>encoded</td><td></td><td>0=Did not have a CABG procedure before baseline || 1=Had a CABG procedure before baseline</td></tr><tr><td>cac_score_1</td><td>Coronary artery calcification (CAC) score using Agatston scoring of CT scan(s) of coronary arteries</td><td>decimal</td><td></td><td></td></tr><tr><td>cac_volume_1</td><td>Coronary artery calcium volume using CT scan(s) of coronary arteries</td><td>decimal</td><td>cubic millimeters</td><td></td></tr><tr><td>cad_followup_start_age_1</td><td>Age of subject at the start of the follow-up period during which atherosclerosis events were reviewed and adjudicated.</td><td>decimal</td><td>cad_followup_start_age</td><td></td></tr><tr><td>carotid_plaque_1</td><td>Presence or absence of carotid plaque.</td><td>encoded</td><td></td><td>0=Plaque not present || 1=Plaque present</td></tr><tr><td>carotid_stenosis_1</td><td>Extent of narrowing of the carotid artery.</td><td>encoded</td><td></td><td>0=None || 1=1%-24% || 2=25%-49% || 3=50%-74% || 4=75%-99% || 5=100%</td></tr><tr><td>cd40_1</td><td>Cluster of differentiation 40 ligand (CD40) concentration in blood.</td><td>decimal</td><td>ng/mL</td><td></td></tr><tr><td>chd_death_definite_1</td><td>An indicator of whether the cause of death was determined by medical professionals or technicians to be "definite" coronary heart disease for subjects who died during the follow-up period.</td><td>encoded</td><td></td><td>0=Death did not occur during follow-up, or cause of CHD death was not determined as definite CHD || 1=CHD death occurred during follow-up and was determined as definite</td></tr><tr><td>chd_death_probable_1</td><td>An indicator of whether the cause of death was determined by medical professionals or technicians to be "probable" or "definite" coronary heart disease for subjects who died during the follow-up period.</td><td>encoded</td><td></td><td>0=Death did not occur during follow-up, or cause of CHD death was not determined as definite or probable CHD || 1=CHD death occurred during follow-up and was determined as probable or definite</td></tr><tr><td>cimt_1</td><td>Common carotid intima-media thickness, calculated as the mean of two values: mean of multiple thickness estimates from the left far wall and from the right far wall.</td><td>decimal</td><td>mm</td><td></td></tr><tr><td>cimt_2</td><td>Common carotid intima-media thickness, calculated as the mean of four values: maximum of multiple thickness estimates from the left far wall, left near wall, right far wall, and right near wall.</td><td>decimal</td><td>mm</td><td></td></tr><tr><td>coronary_angioplasty_incident_1</td><td>An indicator of whether a subject had a coronary angioplasty procedure (that was verified by adjudication or by medical professionals) during the follow-up period.</td><td>encoded</td><td></td><td><p>0=Coronary angioplasty procedure did not occur during follow-up || 1=Coronary angioplasty procedure occurred</p><p>during follow-up</p></td></tr><tr><td>coronary_angioplasty_prior_1</td><td>An indicator of whether a subject had a coronary angioplasty procedure prior to the start of the baseline visit.</td><td>encoded</td><td></td><td>0=Did not have a coronary angioplasty procedure before baseline || 1=Had a coronary angioplasty procedure before baseline</td></tr><tr><td>coronary_revacularization_prior_1</td><td>An indicator of whether a subject had a coronary revascularization procedure prior to the start of the baseline visit. This includes angioplasty, CABG, and other coronary revascularization procedures.</td><td>encoded</td><td></td><td>0=Did not have a coronary revascularization procedure before baseline || 1=Had a coronary revascularization procedure before baseline</td></tr><tr><td>current_smoker_baseline_1</td><td>Indicates whether subject currently smokes cigarettes.</td><td>encoded</td><td></td><td>0=Does not currently smoke cigarettes || 1=Currently smokes cigarettes</td></tr><tr><td>crp_1</td><td>C-reactive protein (CRP) concentration in blood.</td><td>decimal</td><td>mg/L</td><td></td></tr><tr><td>eosinophil_ncnc_bld_1</td><td>Count by volume, or number concentration (ncnc), of eosinophils in the blood (bld).</td><td>decimal</td><td>thousands / microliter</td><td></td></tr><tr><td>eselectin_1</td><td>E-selectin concentration in blood.</td><td>decimal</td><td>ng/mL</td><td></td></tr><tr><td>ever_smoker_baseline_1</td><td>Indicates whether subject ever regularly smoked cigarettes.</td><td>encoded</td><td></td><td>0=Never a cigarette smoker || 1=Current or former cigarette smoker</td></tr><tr><td>fasting_lipids_1</td><td>Indicates whether participant fasted for at least eight hours prior to blood draw to measure lipids phenotypes.</td><td>encoded</td><td></td><td>0=Participant did not fast_or fasted for fewer than eight hours prior to measurement of lipids phenotypes. || 1=Participant fasted for at least eight hours prior to measurement of lipids phenotypes</td></tr><tr><td>geographic_site_1</td><td>Recruitment/field center, baseline clinic, or geographic region.</td><td>encoded</td><td></td><td></td></tr><tr><td>hdl_1</td><td>Blood mass concentration of high-density lipoprotein cholesterol</td><td>decimal</td><td>mg/dL</td><td></td></tr><tr><td>height_baseline_1</td><td>Body height at baseline.</td><td>decimal</td><td>cm</td><td></td></tr><tr><td>hematocrit_vfr_bld_1</td><td>Measurement of hematocrit, the fraction of volume (vfr) of blood (bld) that is composed of red blood cells.</td><td>decimal</td><td>% = percentage</td><td></td></tr><tr><td>hemoglobin_mcnc_bld_1</td><td>Measurement of mass per volume, or mass concentration (mcnc), of hemoglobin in the blood (bld).</td><td>decimal</td><td>g / dL = grams per deciliter</td><td></td></tr><tr><td>hispanic_or_latino_1</td><td>Indicator of reported Hispanic or Latino ethnicity.</td><td>encoded</td><td></td><td>ethnicity component dbGaP variable values for a subject were inconsistent/contradictory (e.g. over multiple visits) || Hispanic or Latino || not Hispanic or Latino</td></tr><tr><td>hispanic_subgroup_1</td><td>classification of Hispanic/Latino background for Hispanic/Latino subjects where country or region of origin information is available</td><td>encoded</td><td></td><td>CentralAmerican=Central American || CostaRican=from Costa Rica || Cuban=Cuban || Dominican=Dominican || Mexican=Mexican || PuertoRican=Puerto Rican || SouthAmerican=South American</td></tr><tr><td>icam1_1</td><td>Intercellular adhesion molecule 1 (ICAM1) concentration in blood.</td><td>decimal</td><td>ng/mL</td><td></td></tr><tr><td>il1_beta_1</td><td>Interleukin 1 beta (IL1b) concentration in blood.</td><td>decimal</td><td>pg/mL</td><td></td></tr><tr><td>il10_1</td><td>Interleukin 10 (IL10) concentration in blood.</td><td>decimal</td><td>pg/mL</td><td></td></tr><tr><td>il18_1</td><td>Interleukin 18 (IL18) concentration in blood.</td><td>decimal</td><td>pg/mL</td><td></td></tr><tr><td>il6_1</td><td>Interleukin 6 (IL6) concentration in blood.</td><td>decimal</td><td>pg/mL</td><td></td></tr><tr><td>isoprostane_8_epi_pgf2a_1</td><td>Isoprostane 8-epi-prostaglandin F2 alpha (8-epi-PGF2a) concentration in urine.</td><td>decimal</td><td>pg/mL</td><td></td></tr><tr><td>ldl_1</td><td>Blood mass concentration of low-density lipoprotein cholesterol</td><td>decimal</td><td>mg/dL</td><td></td></tr><tr><td>lipid_lowering_medication_1</td><td>Indicates whether participant was taking any lipid-lowering medication at blood draw to measure lipids phenotypes</td><td>encoded</td><td></td><td>0=Participant was not taking lipid-lowering medication || 1=Participant was taking lipid-lowering medication</td></tr><tr><td>lppla2_act_1</td><td>Activity of lipoprotein-associated phospholipase A2 (LP-PLA2), also known as platelet-activating factor acetylhydrolase, measured in blood.</td><td>decimal</td><td>nmol/min/mL</td><td></td></tr><tr><td>lppla2_mass_1</td><td>Mass of lipoprotein-associated phospholipase A2 (LP-PLA2), also known as platelet-activating factor acetylhydrolase, measured in blood.</td><td>decimal</td><td>ng/mL</td><td></td></tr><tr><td>lymphocyte_ncnc_bld_1</td><td>Count by volume, or number concentration (ncnc), of lymphocytes in the blood (bld).</td><td>decimal</td><td>thousands / microliter</td><td></td></tr><tr><td>mi_incident_1</td><td>An indicator of whether a subject had a myocardial infarction (MI) event (that was verified by adjudication or by medical professionals) during the follow-up period.</td><td>encoded</td><td></td><td>0=MI event did not occur during follow-up || 1=MI event occurred during follow-up</td></tr><tr><td>mi_prior_1</td><td>An indicator of whether a subject had a myocardial infarction (MI) prior to the start of the baseline visit.</td><td>encoded</td><td></td><td>0=Did not have a history of MI before baseline || 1=Had a history of MI before baseline</td></tr><tr><td>mch_entmass_rbc_1</td><td>Measurement of the average mass (entmass) of hemoglobin per red blood cell(rbc), known as mean corpuscular hemoglobin (MCH).</td><td>decimal</td><td>pg = picogram</td><td></td></tr><tr><td>mchc_mcnc_rbc_1</td><td>Measurement of the mass concentration (mcnc) of hemoglobin in a given volume of packed red blood cells (rbc), known as mean corpuscular hemoglobin concentration (MCHC).</td><td>decimal</td><td>g /dL = grams per deciliter</td><td></td></tr><tr><td>mcp1_1</td><td>Monocyte chemoattractant protein-1 (MCP1), also known as C-C motif chemokine ligand 2, concentration in blood.</td><td>decimal</td><td>pg/mL</td><td></td></tr><tr><td>mmp9_1</td><td>Matrix metalloproteinase 9 (MMP9) concentration in blood.</td><td>decimal</td><td>ng/mL</td><td></td></tr><tr><td>mcv_entvol_rbc_1</td><td>Measurement of the average volume (entvol) of red blood cells (rbc), known as mean corpuscular volume (MCV).</td><td>decimal</td><td>fL = femtoliter</td><td></td></tr><tr><td>monocyte_ncnc_bld_1</td><td>Count by volume, or number concentration (ncnc), of monocytes in the blood (bld).</td><td>decimal</td><td>thousands / microliter</td><td></td></tr><tr><td>mpo_1</td><td>Myeloperoxidase (MPO) concentration in blood.</td><td>decimal</td><td>ng/mL</td><td></td></tr><tr><td>neutrophil_ncnc_bld_1</td><td>Count by volume, or number concentration (ncnc), of neutrophils in the blood (bld).</td><td>decimal</td><td>thousands / microliter</td><td></td></tr><tr><td>opg_1</td><td>Osteoprotegerin (OPG) concentration in blood.</td><td>decimal</td><td>pmol/L</td><td></td></tr><tr><td>pad_incident_1</td><td>An indicator of whether a subject had peripheral arterial disease (that was verified by adjudication or by medical professionals) during the follow-up period.</td><td>encoded</td><td></td><td>0=No diagnosis of PAD during follow-up || 1=PAD was diagnosed during follow-up</td></tr><tr><td>pad_prior_1</td><td>An indicator of whether a subject had peripheral arterial disease prior to the baseline visit.</td><td>encoded</td><td></td><td>0=Did not have a history of PAD before baseline || 1=Had a history of PAD before baseline</td></tr><tr><td>platelet_ncnc_bld_1</td><td>Count by volume, or number concentration (ncnc), of platelets in the blood (bld).</td><td>integer</td><td>thousands / microliter</td><td></td></tr><tr><td>pmv_entvol_bld_1</td><td>Measurement of the mean volume (entvol) of platelets in the blood (bld), known as mean platelet volume (MPV or PMV).</td><td>decimal</td><td>fL = femtoliter</td><td></td></tr><tr><td>pselectin_1</td><td>P-selectin concentration in blood.</td><td>decimal</td><td>ng/mL</td><td></td></tr><tr><td>race_us_1</td><td>Harmonized race category of participant.</td><td>encoded</td><td></td><td>AI_AN=American Indian_Alaskan Native or Native American || Asian=Asian || Black=Black or African American || HI_PI=Native Hawaiian or other Pacific Islander || Multiple=More than one race || Other=Other race || White=White or Caucasian</td></tr><tr><td>rbc_ncnc_bld_1</td><td>Count by volume, or number concentration (ncnc), of red blood cells in the blood (bld).</td><td>decimal</td><td>millions / microliter</td><td></td></tr><tr><td>rdw_ratio_rbc_1</td><td>Measurement of the ratio of variation in width to the mean width of the red blood cell (rbc) volume distribution curve taken at +/- 1 CV, known as red cell distribution width (RDW).</td><td>decimal</td><td>% = percentage</td><td></td></tr><tr><td>sleep_duration_1</td><td>Usual amount of time slept per day.</td><td>decimal</td><td>hours/day</td><td></td></tr><tr><td>subcohort_1</td><td>A distinct subgroup within a study, generally indicating subjects who share similar characteristics due to study design. Subjects may belong to only one subcohort.</td><td>encoded</td><td></td><td></td></tr><tr><td>tnfa_1</td><td>Tumor necrosis factor alpha (TNFa) concentration in blood.</td><td>decimal</td><td>pg/mL</td><td></td></tr><tr><td>tnfa_r1_1</td><td>Tumor necrosis factor alpha receptor 1 (TNFa-R1) concentration in blood.</td><td>decimal</td><td>pg/mL</td><td></td></tr><tr><td>tnfr2_1</td><td>Tumor necrosis factor receptor 2 (TNFR2) concentration in blood.</td><td>decimal</td><td>pg/mL</td><td></td></tr><tr><td>total_cholesterol_1</td><td>Blood mass concentration of total cholesterol</td><td>decimal</td><td>mg/dL</td><td></td></tr><tr><td>triglycerides_1</td><td>Blood mass concentration of triglycerides</td><td>decimal</td><td>mg/dL</td><td></td></tr><tr><td>vte_case_status_1</td><td>An indicator of whether a subject experienced a venous thromboembolism event (VTE) that was verified by adjudication or by medical professionals.</td><td>encoded</td><td></td><td>0=Not known to ever have a VTE event_either self-reported or from medical records || 1=Experienced a VTE event as verified by adjudication or by medical professionals</td></tr><tr><td>vte_followup_start_age_1</td><td>Age of subject at the start of the follow up period during which venous thromboembolism (VTE) events were reviewed and adjudicated.</td><td>decimal</td><td>years</td><td></td></tr><tr><td>vte_prior_history_1</td><td>An indicator of whether a subject had a venous thromboembolism (VTE) event prior to the start of the medical review process (including self-reported events).</td><td>encoded</td><td></td><td>0=did not have prior VTE event || 1=had prior VTE event</td></tr><tr><td>wbc_ncnc_bld_1</td><td>Count by volume, or number concentration (ncnc), of white blood cells in the blood (bld).</td><td>decimal</td><td>thousands / microliter</td><td></td></tr><tr><td>weight_baseline_1</td><td>Body weight at baseline.</td><td>decimal</td><td>kg</td><td></td></tr><tr><td>age_at_*</td><td>For each phenotypic value for a given subject, an associated age at measurement is provided.</td><td>decimal</td><td>years</td><td>See <a href="https://topmed.nhlbi.nih.gov/dcc-harmonized-phenotypes">TOPMed Harmonization Strategies </a>for more information.</td></tr><tr><td>unit_*</td><td>For each harmonized variable, a paired “unit_variable” is provided, whose value indicates where in the documentation to look to find the set of component variables and the algorithm used to harmonize those variables.</td><td>encoded</td><td></td><td>See <a href="https://topmed.nhlbi.nih.gov/dcc-harmonized-phenotypes">TOPMed Harmonization Strategies </a>for more information.</td></tr></tbody></table>